Abstract:Summary Neurodegenerative diseases are characterized by numerous markers of progression and clinical endpoints. For instance, multiple system atrophy (MSA), a rare neurodegenerative synucleinopathy, is characterized by various combinations of progressive autonomic failure and motor dysfunction, and a very poor prognosis. Describing the progression of such complex and multi‐dimensional diseases is particularly difficult. One has to simultaneously account for the assessment of multivariate markers over time, the occurrence of clinical endpoints, and a highly suspected heterogeneity between patients. Yet, such description is crucial for understanding the natural history of the disease, staging patients diagnosed with the disease, unravelling subphenotypes, and predicting the prognosis. Through the example of MSA progression, we show how a latent class approach modeling multiple repeated markers and clinical endpoints can help describe complex disease progression and identify subphenotypes for exploring new pathological hypotheses. The proposed joint latent class model includes class‐specific multivariate mixed models to handle multivariate repeated biomarkers possibly summarized into latent dimensions and class‐and‐cause‐specific proportional hazard models to handle time‐to‐event data. Maximum likelihood estimation procedure, validated through simulations is available in the lcmm R package. In the French MSA cohort comprising data of 598 patients during up to 13 years, five subphenotypes of MSA were identified that differ by the sequence and shape of biomarkers degradation, and the associated risk of death. In posterior analyses, the five subphenotypes were used to explore the association between clinical progression and external imaging and fluid biomarkers, while properly accounting for the uncertainty in the subphenotypes membership.

Composite likelihood and maximum likelihood methods for joint latent class modeling of disease prevalence and high-dimensional semicontinuous biomarker data

Composite likelihood and maximum likelihood methods for joint latent class modeling of disease prevalence and high-dimensional semicontinuous biomarker data

Maximum Likelihood Estimation for Semiparametric Regression Models with Interval-Censored Multi-State Data

Maximum likelihood estimation for semiparametric regression models with interval-censored multistate data

Latent Class Analysis with Semi-parametric Proportional Hazards Submodel for Time-to-event Data

Maximum likelihood estimation of semiparametric mixture component models for competing risks data

Likelihood-based Quantile Mixed Effects Models for Longitudinal Data with Multiple Features Via MCEM Algorithm

A joint latent class model of longitudinal and survival data with a time-varying membership probability

Describing complex disease progression using joint latent class models for multivariate longitudinal markers and clinical endpoints

Evaluating the association between latent classes and competing risks outcomes with multiphenotype data

Semiparametric maximum likelihood estimation with two-phase stratified case-control sampling

Latent Class Dynamic Mediation Model with Application to Smoking Cessation Data

SEMIPARAMETRIC LATENT-CLASS MODELS FOR MULTIVARIATE LONGITUDINAL AND SURVIVAL DATA

Simultaneous Modeling of Multivariate Heterogeneous Responses and Heteroskedasticity Via a Two‐stage Composite Likelihood

Latent Class Proportional Hazards Regression with Heterogeneous Survival Data

Employing latent variable models to improve efficiency in composite endpoint analysis

Semiparametric Estimation for the Non-Mixture Cure Model in Case-Cohort and Nested Case-Control Studies

Composite likelihood for extreme values

Generalized Linear Latent Variable Modeling for Multi-Group Studies

Maximum Likelihood Estimations and EM Algorithms with Length-biased Data

Bayesian Composite Quantile Regression for Linear Mixed-Effects Models